FDA Approves Merck’s Welireg + Keytruda in Adjuvant ccRCC
Oncology Intelligence — June 16, 2026
|
Merck’s Welireg-Keytruda combination won FDA approval on June 12, 2026 for adjuvant clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, cutting the risk of recurrence, metastasis, or death by 28% in the 1,841-patient Phase 3 LITESPARK-022 trial — while Eli Lilly posted early Phase 1 myelofibrosis data on its Ajax-acquired Type II JAK2 inhibitor at EHA 2026 and Soligenix terminated its failed Phase 3 cutaneous T-cell lymphoma program.
Today’s top developments:
|
What to Watch
- Merck’s adjuvant RCC label expansions — Watch for Merck to pursue additional Welireg + Keytruda label expansions (including potential neoadjuvant ccRCC and other VHL-pathway tumors) following the June 12, 2026 adjuvant approval, further widening its lead given that no other large pharma has cleared an adjuvant RCC IO trial.
- Lilly Type II JAK2 inhibitor Phase 2 readout — Lilly’s Type II JAK2 inhibitor Phase 2 dose-expansion data at ASH 2026 or EHA 2027 will determine whether the asset justifies accelerated development timelines and potential priority-review pursuit in post-ruxolitinib myelofibrosis.
- Soligenix M&A exploration — Soligenix’s M&A exploration is unlikely to attract premium interest given the failed lead asset; watch for a distressed-price acquisition targeting any surviving non-oncology pipeline rather than a CTCL-focused deal.
- NCI osimertinib +/- bevacizumab readout (NCT04181060) — NCI’s osimertinib +/- bevacizumab trial (NCT04181060) readout could directly challenge AstraZeneca’s Tagrisso monotherapy standard in EGFR-mutant NSCLC if combination benefit exceeds 4-6 months additional PFS.
This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.